Belite Bio, Inc.

Belite Bio submits drug application in Japan for Stargardt disease

Markets 15 d ago 3 sources

Belite Bio On Track For A Potential Blockbuster Launch In 2027

Markets 15 d ago

H.C. Wainwright reiterates Belite Bio stock rating on commercial plans

Markets 21 d ago 2 sources

Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript

Markets 21 d ago